Amid the sturm und drang over Inflation Reduction Act (IRA) drug price negotiations, Bristol Myers Squibb has been among the ...
Johnson & Johnson’s latest attempt to get a handle on its talc litigation using the controversial Texas two-step bankruptcy ...
Eisai, Biogen's Alzheimer's med Leqembi turned down in Europe—but analyst says it's merely a 'delay'
Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid ...
Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star ...
While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of ...
After Eli Lilly’s Olumiant won the distinction of becoming the first med approved by the FDA to treat the follicle-attacking ...
AbbVie could have the hottest cancer drug launch of 2025 on its hands. | AbbVie could have the hottest cancer drug launch of ...
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the ...
Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of ...
FDA advisers, frustrated by AZ's Imfinzi design, call for revamp of perioperative lung cancer trials
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial ...
Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the ...
Among AstraZeneca’s growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results